[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"guillain-barr-syndrome-gbs\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:guillain-barr-syndrome-gbs":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,82],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100641464","cohort-study-on-neuroimmune-diseases-in-the-reproductive-age-100641464",false,"NCT07653984","Cohort Study on Neuroimmune Diseases in the Reproductive Age","RANID","Inclusion Criteria:\n\n* Patient Group: A total of fifty participants are expected to be enrolled.\n\n  1. Women aged 20-55 years with childbearing potential.\n  2. Voluntary informed consent.\n  3. Availability of complete personal information.\n  4. A confirmed diagnosis of neuromyelitis optica spectrum disorder (NMOSD), multiple sclerosis (MS), autoimmune encephalitis, myasthenia gravis, Guillain-Barré syndrome, or myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).\n\nHealthy Control Group: A total of fifty healthy women are expected to be included.\n\n1. Age- and sex-matched women of childbearing age with plans for pregnancy\n2. Voluntary informed consent.\n3. Availability of complete personal information.\n\nExclusion Criteria:\n\n* Patient Group:\n\n  1. Patients with an undetermined or unconfirmed diagnosis.\n  2. Incomplete personal information that cannot be obtained through follow-up.\n  3. Participants who voluntarily withdrew from the study and revoked informed consent.\n\nHealthy Control Group:\n\n1. Individuals diagnosed with neuroimmune-related disorders.\n2. Incomplete personal information that cannot be obtained through follow-up.\n3. Participants who voluntarily withdrew from the study and revoked informed consent.",true,"FEMALE","20 Years","55 Years",{"count":21,"type":22},100,"ESTIMATED","OBSERVATIONAL","Neuroimmune diseases are more prevalent among women of reproductive age. Studies have shown that neuroimmune diseases may impact fertility. Therefore, effective management of neuroimmune diseases during pregnancy is particularly important. This study included a follow-up period of up to five years in patients with pregnancy-associated neuroimmune disorders. Data collected included relapse frequency, symptomatology, imaging findings, treatment regimens, peripheral blood profiles, EDSS scores, and MRI results. In addition, maternal drug concentrations, postpartum relapse rates, and neonatal development were monitored after delivery. Following the successful completion of the five-year follow-up, the research team plans to continue the prospective epidemiological study with ten-year follow-up phases. The aim of this study is to generate detailed clinical data on pregnancy-associated autoimmune diseases and to equip clinicians with evidence-based strategies for optimizing disease management during the reproductive age.",[26,27,28,29,30,31],"Neuromyelitis Optica Spectrum Disorders (NMOSD)","Multiple Sclerosis","Autoimmune Encephalitis","Myasthenia Gravis","Guillain-Barré Syndrome (GBS)","Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)",[33,27,34,35,30,31,36,37],"Neuromyelitis optica spectrum disorders (NMOSD)","Autoimmune encephalitis","myasthenia gravis","reproductive age","cohort study","RECRUITING","2026-06-13",{"date":41,"type":42},"2026-06-17","ACTUAL",{"date":44,"type":42},"2024-04-21",{"date":46,"type":22},"2030-04",{"name":48,"class":49},"Third Affiliated Hospital, Sun Yat-Sen University","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100588400","living-with-guillain-barr-syndrome-as-children-100588400","NCT06940908","Living With Guillain-Barré Syndrome as Children.","Experience of Guillain Barré Syndrome in Childhood: A French Multicentric Qualitative Study","GUIREQUAL","Inclusion Criteria:\n\n* Children or adolescents aged 10 years or older at the time of the interview\n* History of Guillain-Barré syndrome (GBS) diagnosed in childhood\n* Time since acute episode: between 2 and 5 years\n* Sufficient mastery of the French language to participate in a semi-structured interview\n* Consent of the participant and, for minors, parental consent\n\nExclusion Criteria:\n\n* Presence of a neurological disease other than GBS that may interfere with participation or interpretation of data\n* Severe cognitive impairment preventing the child or adolescent from engaging in the interview","ALL","10 Years","18 Years",{"count":63,"type":22},25,"The goal of this qualitative observational study is to explore the lived experience and psychological aftermath of children who were affected by Guillain-Barré Syndrome (GBS) two to five years earlier. GBS is a rare and acute neurological condition, and while motor recovery is generally good in children, residual symptoms such as fatigue, pain, anxiety, or depression may persist and impact quality of life.\n\nThe main questions it aims to answer are:\n\nHow do children experience and recall their illness and recovery after GBS? What psychological or contextual factors might contribute to emotional distress or depressive symptoms in the years following the disease?\n\nParticipants will:\n\nBe children aged 10 or older who had GBS two to five years prior. Participate in a 45-60-minute semi-structured individual interview during a routine follow-up visit.\n\nRespond to a screening questionnaire for depressive symptoms (Children's Depression Inventory or Beck Depression Inventory Fast Screen).\n\nUndergo a brief clinical examination to assess any remaining physical sequelae. Interviews will be audio recorded, transcribed verbatim, and pseudonymized. Thematic reflexive analysis will be performed following Braun and Clarke's methodology. Recruitment will continue until theoretical saturation is reached (approximately 25 participants expected) across two centers (Toulouse and Montpellier).\n\nThis study aims to generate new insights into pediatric psychological outcomes after GBS, in order to improve acute care and follow-up, and potentially guide future mental health support for affected children.",[66,30],"Guillain Barré Syndrome",[68,69,70,71],"children","experience","qualitative study","quality of life","2026-05-07",{"date":74,"type":42},"2026-05-08",{"date":76,"type":42},"2025-05-05",{"date":78,"type":22},"2027-06-01",{"name":80,"class":49},"University Hospital, Toulouse",2,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":16,"sex":59,"minAge":61,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":103,"leadSponsor":105,"locationsCount":4},"100602321","multispectral-optoacoustic-imaging-for-the-detection-of-inflammation-and-damage-of-peripheral-nerves-in-guillain-barr-syndrome-and-chronic-inflammatory-demyelinating-polyneuropathy-100602321","NCT07121985","Multispectral Optoacoustic Imaging for the Detection of Inflammation and Damage of Peripheral Nerves in Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy","MIND","Inclusion Criteria Patient Cohort(s):\n\n* Established diagnosis or suspected CIDP or GBS\n* Age: 18 years or older\n* Written informed consent provided by participant\n\nInclusion Criteria Control Cohort:\n\n* Written informed consent provided by participant\n* Age: 18 years or older\n* No pre-existing conditions that may affect peripheral nerves (e.g., diabetes, traumatic nerve injuries, etc.)\n\nExclusion Criteria:\n\n* Pregnancy\n* Breastfeeding mothers\n* Cardiopulmonary instability\n* Tattoo in the examination area\n* Subcutaneous fat tissue \\> 3 cm",{"count":90,"type":22},30,"The aim of this study is to assess disease activity in patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Guillain-Barré Syndrome (GBS) using multispectral optoacoustic tomography (MSOT).\n\nThe currently available diagnostic procedures for CIDP and GBS do not allow for a clear distinction between remission and active disease and show limitations in sensitivity and specificity during acute diagnostics. This can lead to delayed diagnosis, which is crucial for timely initiation of therapy and, consequently, for a better prognosis. Long-term therapy management is also challenging, as objective parameters for assessing therapeutic success are largely lacking.\n\nMSOT can detect inflammation through the measurement of hemoglobin, a method that our research group has already successfully demonstrated in patients with chronic inflammatory bowel diseases (Knieling, NEJM 2017). The use of MSOT could therefore also be applied to nerve inflammation, allowing for earlier detection of inflammation and nerve damage and contributing to timely treatment of patients.\n\nFor nerve imaging, a CE-certified MSOT device from iThera Medical is available at the Pediatric Clinic in Erlangen. In addition, a non-CE-certified device with lower laser power is available, which can be used for bedside examinations.\n\nThe arm nerves will be examined in three cohorts, which will be compared with each other and with standard diagnostics (blood tests, electrophysiology, conventional ultrasound).\n\nEach cohort will include ten healthy control subjects, ten patients with CIDP, and ten patients with GBS.",[93,30],"CIDP - Chronic Inflammatory Demyelinating Polyneuropathy",[95,96,97],"MSOT","PAI","Nerve Ultrasound","NOT_YET_RECRUITING","2025-08-06",{"date":101,"type":42},"2025-08-14",{"date":99,"type":22},{"date":104,"type":22},"2027-08-06",{"name":106,"class":49},"University of Erlangen-Nürnberg Medical School"]